These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17075582)

  • 1. Computerized morphometry as an aid in determining the grade of dysplasia and progression to adenocarcinoma in Barrett's esophagus.
    Sabo E; Beck AH; Montgomery EA; Bhattacharya B; Meitner P; Wang JY; Resnick MB
    Lab Invest; 2006 Dec; 86(12):1261-71. PubMed ID: 17075582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
    Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
    Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression from low-grade dysplasia to malignancy in patients with Barrett's esophagus diagnosed by two or more pathologists.
    Moole H; Patel J; Ahmed Z; Duvvuri A; Vennelaganti S; Moole V; Dharmapuri S; Boddireddy R; Yedama P; Bondalapati N; Uppu A; Vennelaganti P; Puli S
    World J Gastroenterol; 2016 Oct; 22(39):8831-8843. PubMed ID: 27818599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Routine morphometrical analysis can improve reproducibility of dysplasia grade in Barrett's oesophagus surveillance biopsies.
    Baak JP; ten Kate FJ; Offerhaus GJ; van Lanschot JJ; Meijer GA
    J Clin Pathol; 2002 Dec; 55(12):910-6. PubMed ID: 12461055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation.
    Polkowski W; Baak JP; van Lanschot JJ; Meijer GA; Schuurmans LT; Ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 1998 Feb; 184(2):161-8. PubMed ID: 9602707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.
    Horvath B; Singh P; Xie H; Thota PN; Allende DS; Pai RK; Patil DT; Plesec TP; Goldblum JR; Liu X
    J Gastroenterol Hepatol; 2015 Feb; 30(2):262-7. PubMed ID: 25087917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification of patients with barrett's esophagus and low-grade dysplasia or indefinite for dysplasia.
    Thota PN; Lee HJ; Goldblum JR; Liu X; Sanaka MR; Gohel T; Kanadiya M; Lopez R
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):459-465.e1. PubMed ID: 25102445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia.
    Henn AJ; Song KY; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Sep; 33(9):. PubMed ID: 32399569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computerized quantitative pathology for the grading of dysplasia in surveillance biopsies of Barrett's oesophagus.
    van Sandick JW; Baak JP; van Lanschot JJ; Polkowski W; ten Kate FJ; Obertop H; Offerhaus GJ
    J Pathol; 2000 Feb; 190(2):177-83. PubMed ID: 10657016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
    Morris CD; Armstrong GR; Bigley G; Green H; Attwood SE
    Am J Gastroenterol; 2001 Apr; 96(4):990-6. PubMed ID: 11316217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
    Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
    Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel.
    Duits LC; Phoa KN; Curvers WL; Ten Kate FJ; Meijer GA; Seldenrijk CA; Offerhaus GJ; Visser M; Meijer SL; Krishnadath KK; Tijssen JG; Mallant-Hent RC; Bergman JJ
    Gut; 2015 May; 64(5):700-6. PubMed ID: 25034523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's Registry Collaboration of academic centers in Ireland reveals high progression rate of low-grade dysplasia and low risk from nondysplastic Barrett's esophagus: report of the RIBBON network.
    O'Byrne LM; Witherspoon J; Verhage RJJ; O'Brien M; Muldoon C; Ryan C; Buckley M; Murphy T; Reynolds R; Patchett S; Kay E; Azam H; Robb W; Arumugasamy M; Mathuna PM; Leyden J; Gargan S; Doherty G; Sheahan K; Collins C; Nath A; O'Sullivan J; Donohoe CL; Ravi N; O'Toole D; Reynolds JV
    Dis Esophagus; 2020 Oct; 33(10):. PubMed ID: 32193532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Independent Blinded Validation of a Tissue Systems Pathology Test to Predict Progression in Patients With Barrett's Esophagus.
    Davison JM; Goldblum J; Grewal US; McGrath K; Fasanella K; Deitrick C; DeWard AD; Bossart EA; Hayward SL; Zhang Y; Critchley-Thorne RJ; Thota PN
    Am J Gastroenterol; 2020 Jun; 115(6):843-852. PubMed ID: 32079863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus.
    Wani S; Falk GW; Post J; Yerian L; Hall M; Wang A; Gupta N; Gaddam S; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Goldblum J; Lieberman DA; Sampliner RE; Sharma P
    Gastroenterology; 2011 Oct; 141(4):1179-86, 1186.e1. PubMed ID: 21723218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and grading of dysplasia in Barrett's oesophagus.
    Odze RD
    J Clin Pathol; 2006 Oct; 59(10):1029-38. PubMed ID: 17021130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and risk stratification of Barrett's dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue.
    Choi WT; Tsai JH; Rabinovitch PS; Small T; Huang D; Mattis AN; Kakar S
    Gut; 2018 Jul; 67(7):1229-1238. PubMed ID: 28642331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.